Identification of a class of potent USP25/28 inhibitors with broad-spectrum anti-cancer activity

Affiliations

• ¹ Zhejiang Provincial Key Laboratory of Pancreatic Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China.
• ² Shanghai Institute of Materia Medica, Shanghai, 200216, China.
• ³ Chaser Therapeutics, Inc., Hangzhou, Zhejiang Province, 310018, China.
• ⁴ Beijing Advanced Innovation Center for Structural Biology, School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.
• ⁵ Zhejiang Provincial Key Laboratory of Pancreatic Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China. liangtingbo@zju.edu.cn.
• ⁶ Shanghai Institute of Materia Medica, Shanghai, 200216, China. chtan@simm.ac.cn.
• ⁷ Zhejiang Provincial Key Laboratory of Pancreatic Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China. pzhangbcm@zju.edu.cn.